



Eleison Pharmaceuticals Announces the Appointment of Baruch S. Blumberg, MD, PhD to its Science Advisory Board

Princeton, NJ, July 7, 2010 -- Eleison Pharmaceuticals, Inc., a specialty pharmaceutical company developing life-saving therapeutics for rare cancers, has announced the appointment of Dr. Baruch Blumberg to the company's Science Advisory Board (SAB). Dr. Blumberg is a world-renowned scientist and a recipient of the Nobel Prize in Medicine.

"The appointment of Dr. Blumberg to the Eleison SAB represents a significant addition to the Company's scientific resources," said Forrest Anthony, MD, Chief Medical Officer and President of Eleison Pharmaceuticals. "Dr. Blumberg's contributions to science include the development of the first hepatitis B vaccine, which has likely prevented more cancer deaths than any other therapeutic or vaccine in history."

Dr. Blumberg commented, "There exists today a desperate need for new oncology drugs to treat less common cancers largely ignored by the major pharmaceutical companies." "I am pleased and look forward to working with an Eleison team committed to meeting this need and helping rare cancer patient populations."

About Dr. Baruch Blumberg:

The research, discoveries and vision of Baruch S. Blumberg, MD, PhD, have had a far-reaching impact on public health around the globe. He was awarded the Nobel Prize in Medicine for his work in the discovery of the hepatitis B virus, the primary cause of hepatocellular carcinoma. He is a member of the National Academy of Sciences, the American Philosophical Society, and the National Inventors Hall of Fame. Dr. Blumberg is the former head of Oxford's Balliol College and the former director of the NASA Astrobiology Institute, and continues to maintain academic appointments at the University of Pennsylvania and the Fox Chase Cancer Center.

About Eleison Pharmaceuticals:

Eleison's mission is to acquire, develop, and commercialize clinical stage drug candidates for "orphan" indications, providing new hope for patients with rare life-threatening diseases. The Company plans to begin later this year a phase III clinical study of its lead drug candidate, glufosfamide, for pancreatic cancer. Founded in 2008 and headquartered in Princeton, NJ, Eleison is in discussions to acquire other promising programs for rare cancers

Forward Looking Statements

Except for statements of historical fact, the statements in this press release are forward-looking statements, including statements regarding Eleison's product candidates, their uses and potential benefits and clinical trial results and plans. These statements involve risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties include, but are not limited to, Eleison's ability to enroll and complete its current and anticipated clinical trials, the time and expense required to conduct such clinical trials and analyze data, the possibility that results from these trials will not be confirmed, potential adverse side effects, issues arising in the regulatory or manufacturing process and the results of such clinical trials (including product safety issues and efficacy results). Eleison does not intend to update any forward-looking statement made in this news release.

SOURCE: Eleison Pharmaceuticals, Inc.
CONTACT: Eleison Pharmaceuticals, Inc.
Corporate Communications
103 Carnegie Center, Suite 300
Princeton, NJ 08504
215-416-7620
info@eleison-pharma.com